These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10401710)

  • 1. Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.
    Guzzaloni G; Grugni G; Morabito F
    J Endocrinol Invest; 1999 May; 22(5):360-8. PubMed ID: 10401710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth hormone response to hexarelin, growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen in prepubertal and early pubertal short children.
    Guzzaloni G; Grugni G; Morabito F
    Minerva Endocrinol; 1998 Dec; 23(4):99-104. PubMed ID: 10361807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhancement of cholinergic tone by pyridostigmine promotes both basal and growth hormone (GH)-releasing hormone-induced GH secretion in children of short stature.
    Ghigo E; Mazza E; Imperiale E; Rizzi G; Benso L; Müller EE; Camanni F; Massara F
    J Clin Endocrinol Metab; 1987 Sep; 65(3):452-6. PubMed ID: 3114300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose hexarelin and growth hormone (GH)-releasing hormone as a diagnostic tool for the diagnosis of GH deficiency in adults: comparison with insulin-induced hypoglycemia test.
    Gasperi M; Aimaretti G; Scarcello G; Corneli G; Cosci C; Arvat E; Martino E; Ghigo E
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2633-7. PubMed ID: 10443652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone.
    Ghigo E; Imperiale E; Boffano GM; Mazza E; Bellone J; Arvat E; Procopio M; Goffi S; Barreca A; Chiabotto P
    J Endocrinol Invest; 1990 Apr; 13(4):307-16. PubMed ID: 2115060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.
    Arvat E; Maccario M; Di Vito L; Broglio F; Benso A; Gottero C; Papotti M; Muccioli G; Dieguez C; Casanueva FF; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1169-74. PubMed ID: 11238504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients.
    Grottoli S; Razzore P; Arvat E; Oleandri SE; Rossetto R; Ciccarelli E; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Nov; 20(10):597-602. PubMed ID: 9438917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hexarelin, a synthetic GH-releasing peptide, is a powerful stimulus of GH secretion in pubertal children and in adults but not in prepubertal children and in elderly subjects.
    Bellone J; Bartolotta E; Sgattoni C; Aimaretti G; Arvat E; Bellone S; Deghenghi R; Ghigo E
    J Endocrinol Invest; 1998 Sep; 21(8):494-500. PubMed ID: 9801989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of hexarelin in man.
    Arvat E; Di Vito L; Gianotti L; Ramunni J; Boghen MF; Deghenghi R; Camanni F; Ghigo E
    Metabolism; 1997 Jan; 46(1):83-8. PubMed ID: 9005975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons among old and new provocative tests of GH secretion in 178 normal adults.
    Aimaretti G; Baffoni C; DiVito L; Bellone S; Grottoli S; Maccario M; Arvat E; Camanni F; Ghigo E
    Eur J Endocrinol; 2000 Apr; 142(4):347-52. PubMed ID: 10754475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of food intake in the modulation of hexarelin-induced growth hormone release in normal human subjects.
    De Marinis L; Mancini A; Valle D; Izzi D; Bianchi A; Gentilella R; Giampietro A; Desenzani P; Giustina A
    Horm Metab Res; 2000 Apr; 32(4):152-6. PubMed ID: 10824712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.
    Aimaretti G; Baffoni C; Bellone S; Di Vito L; Corneli G; Arvat E; Benso L; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3693-9. PubMed ID: 11061526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Administration of arginine plus growth hormone releasing hormone to evaluate growth hormone (GH) secretory status in children with GH deficiency.
    Keller A; Donaubauer J; Kratzsch J; Pfaeffle R; Hirsch W; Kiess W; Keller E
    J Pediatr Endocrinol Metab; 2007 Dec; 20(12):1307-14. PubMed ID: 18341090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of recombinant human insulin-like growth factor I administration on growth hormone (GH) secretion, both spontaneous and stimulated by GH-releasing hormone or hexarelin, a peptidyl GH secretagogue, in humans.
    Ghigo E; Gianotti L; Arvat E; Ramunni J; Valetto MR; Broglio F; Rolla M; Cavagnini F; Müller EE
    J Clin Endocrinol Metab; 1999 Jan; 84(1):285-90. PubMed ID: 9920097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unaltered ratio of circulating levels of growth hormone/GH isoforms in adults with Prader-Willi syndrome after GHRH plus arginine administration.
    Rigamonti AE; Grugni G; Marazzi N; Bini S; Bidlingmaier M; Sartorio A
    Growth Horm IGF Res; 2015 Aug; 25(4):168-73. PubMed ID: 26059749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man.
    Arvat E; Maccagno B; Ramunni J; Gianotti L; Di Vito L; Deghenghi R; Camanni F; Ghigo E
    J Endocrinol Invest; 1997 Mar; 20(3):122-7. PubMed ID: 9186817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan.
    Valetto MR; Bellone J; Baffoni C; Savio P; Aimaretti G; Gianotti L; Arvat E; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Nov; 135(5):568-72. PubMed ID: 8980159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.